Catalog No.
Product Name
Application
Product Information
Citations
-
E3 ligase ligand-linker conjugate
Pomalidomide-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a PEG linker used in PROTAC technology. -
CRBN degrader
PROTAC CRBN Degrader-1 comprises a cereblon (CRBN) ligand binding group, a linker and an von Hippel-Landau (VHL) binding group. PROTAC CRBN Degrader-1 is an cereblon (CRBN) degrader. -
PROTAC linker
Bis-NH2-C1-PEG3 (PROTAC Linker 24) is a PROTAC linker, which refers to the alkyl/ether composition. Bis-NH2-C1-PEG3 can be used in the synthesis of a series of PROTACs. -
ERRa degrader
PROTAC ERRalpha Degrader-2 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRalpha Degrader-2 is an estrogen-related receptor alpha (ERRa) degrader. -
ERRα Degrader
PROTAC ERRα Degrader-1 comprises a MDM2 ligand binding group, a linker and an estrogen-related receptor alpha (ERRa) binding group. PROTAC ERRα Degrader-1 is an estrogen-related receptor alpha (ERRa) degrader. -
PROTAC linker
Phenol-amido-C1-PEG3-N3 (PROTAC Linker 21) is a PROTAC linker, which refers to the PEG composition. Phenol-amido-C1-PEG3-N3 can be used in the synthesis of a series of PROTACs. -
PROTAC linker
N3-PEG4-C2-NH2 (PROTAC Linker 20) is a polyethylene glycol (PEG)-based PROTAC linker. N3-PEG4-C2-NH2 can be used in the synthesis of a series of PROTACs. -
ERRα inverse agonist
PROTAC ERRα ligand 2 is an estrogen-related receptor α (ERRα) inverse agonist with an IC50 of 5.67 nM. PROTAC ERRα ligand 2 (IC50=5.67 nM) displays a ~11-fold improved potency than XCT790 (IC50=61.3 nM). -
PROTAC linker
Bis-NH2-PEG2 (PROTAC Linker 19) is a PROTAC linker, which refers to the PEG composition. Bis-NH2-PEG2 can be used in the synthesis of a series of PROTACs. -
PROTAC linker
cIAP1 Ligand-Linker Conjugates 1 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 1 can be used to design SNIPERs. -
PROTAC linker
cIAP1 Ligand-Linker Conjugates 3 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 3 can be used to design SNIPERs. -
PROTAC linker
cIAP1 Ligand-Linker Conjugates 5 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 5 can be used to design SNIPERs. -
PROTAC linker
cIAP1 Ligand-Linker Conjugates 12 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 12 can be used to design SNIPERs. -
PROTAC linker
cIAP1 Ligand-Linker Conjugates 2 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 2 can be used to design SNIPERs. -
PROTAC linker
cIAP1 Ligand-Linker Conjugates 14 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 14 can be used to design SNIPERs. -
PROTAC linker
cIAP1 Ligand-Linker Conjugates 15 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 15 can be used to design SNIPERs. -
PROTAC linker
cIAP1 Ligand-Linker Conjugates 11 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 11 can be used to design SNIPERs. -
E3 ubiquitin ligase ligand
E3 ligase Ligand 14 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 14 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins. -
E3 ubiquitin ligase ligand
E3 ligase Ligand 10 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 10 can be connected to the ligand for protein by a linker to form PROTACs. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins. -
E3 ubiquitin ligase ligand
E3 ligase Ligand 9 is a ligand for E3 ubiquitin ligase. E3 ligase Ligand 9 can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs. -
PROTAC linker
Tos-PEG3-NH-Boc (PROTAC Linker 9) is a PROTAC linker, which refers to the PEG composition. Tos-PEG3-NH-Boc can be used in the synthesis of a series of PROTACs. -
PROTAC linker
PEG3-O-CH2COOH (Compound 15b) is a PROTAC linker can be used in the synthesis of a series of SNIPER(ER)s. -
PROTAC linker
Tos-PEG4-NH-Boc (PROTAC Linker 7) is a PROTAC linker, which refers to the PEG composition. Tos-PEG4-NH-Boc can be used in the synthesis of a series of PROTACs. -
PROTAC linker
Tos-PEG3-O-C1-CH3COO (PROTAC Linker 6) is a PROTAC linker, which refers to the PEGs composition. -
heterobifunctional degrader
FKBP12 PROTAC dTAG-7 (dTAG-7) is a heterobifunctional degrader. -
PROTAC linker
NH2-PEG3-C1-Boc (PROTAC Linker 5) is a PROTAC linker, which refers to the PEG composition. NH2-PEG3-C1-Boc can be used in the synthesis of a series of PROTACs. -
CDK9 degrader PROTAC
THAL-SNS-032 is a selective CDK9 degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN). - Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a VHL ligand via a linker, induces EGFR degradation with DC50s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively.
-
E3 ligase ligand-linker conjugate
Pomalidomide-PEG3-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology. -
FKBP ligand
AP1867-2-(carboxymethoxy), the AP1867 (a synthetic FKBP12F36V-directed ligand) based moiety, binds to CRBN ligand via a linker to form dTAG molecules. - (S,R,S)-AHPC-Me (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader.
-
CRBN degrader
Homo-PROTAC cereblon degrader 1 (compound 15a) is a highly potent and efficient cereblon (CRBN) degrader with only minimal effects on IKZF1 and IKZF3. -
pVHL30 degrader
Homo-PROTAC pVHL30 degrader 1 is a potent pVHL30 degrader based on PROTAC. -
Molecular Glue
(R)-CR8 trihydrochloride is a potent inhibitor of CDK1, CDK2, CDK5, CDK7, and CDK9, functioning as a molecular glue degrader that targets cyclin K. With inhibitory activity characterized by low nanomolar IC50 values, it effectively induces apoptosis while exhibiting neuroprotective properties. This compound is suitable for research applications in cancer biology and neurodegenerative disease studies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-PEG4-NHS ester is a PEG-based linker designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras). It functions as a ligand for E3 ligases, facilitating targeted protein degradation. This compound is instrumental in chemical biology research aimed at exploring pathways involved in protein turnover and has applications in developing therapeutics for diseases driven by dysregulated protein levels. -
Molecular Glues
(S)-Thalidomide is the S-enantiomer of Thalidomide, functioning as a molecular glue. It exerts significant biological activities, including immunomodulation, anti-inflammation, antiangiogenesis, and pro-apoptosis. This compound induces teratogenic effects through its interaction with cereblon (CRBN), making it a valuable tool for research into cell signaling pathways and developmental biology. -
E3 Ligase Ligand-Linker Conjugate
Biotin-Thalidomide is a biotinylated derivative of Thalidomide designed to selectively bind to the cereblon (CRBN) E3 ubiquitin ligase. This compound serves as a crucial ligand-linker conjugate for the development of proteolysis-targeting chimeras (PROTACs). Biotin-Thalidomide facilitates targeted proteasomal degradation of specific proteins, making it a valuable tool for research in targeted protein degradation and molecular biology. Its utility extends to applications in drug discovery and therapeutic development. -
CDK4/6 PROTAC Degrader
PROTAC CDK4/6 degrader 1 is a dual-targeted degrader designed to selectively degrade cyclin-dependent kinases CDK4 and CDK6. With DC50 values of 10.5 nM and 2.5 nM, this compound effectively inhibits cell proliferation in Jurkat cells, demonstrating an IC50 of 0.18 μM. The compound promotes G1 phase cell cycle arrest and triggers apoptosis, making it a valuable tool for studying cancer biology and potential therapeutic applications in CDK-related malignancies. -
CDK12/CCNK Molecular Glue
NCT02 is a molecular glue degrader that targets CDK12 through the E3 ubiquitin ligase DDB1, resulting in the ubiquitination and subsequent proteasomal degradation of its partner protein CCNK. This mechanism leads to the downregulation of CDK12, inhibiting its downstream signaling pathways. NCT02 exhibits significant biological activity by inducing apoptosis in tumor cells, arresting the cell cycle, and selectively inhibiting the proliferation of colorectal cancer cells with TP53 mutations or belonging to the CMS4 molecular subtype. Additionally, NCT02 demonstrates potential in suppressing tumor growth in both in vitro and in vivo models. -
PROTAC Linkers
Thalidomide-O-amido-PEG4-azide is a PEG-based linker designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras). This compound possesses an azide group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with alkyne-containing molecules. Additionally, it can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN functionalized compounds. This makes Thalidomide-O-amido-PEG4-azide a versatile tool in targeted protein degradation applications and chemical biology research. -
CCND1/CDK4 PROTAC Degrader
CPD-10 is a targeted CCND1 and CDK4 PROTAC degrader that effectively promotes the degradation of these proteins. Exhibiting significant anti-proliferative activity, CPD-10 induces apoptosis in cancer cell lines. It decreases the expression levels of cyclin D1, cyclin D3, CDK4, and phosphorylated Rb at serines 5807 and 811 in a dose-dependent manner, making it a valuable tool for research in cancer biology and therapeutic applications targeting cell cycle regulation.
